These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1013 related items for PubMed ID: 30120038
1. 68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli? Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, Maes A, Mokgoro NP, Van de Wiele C, Vorster M, Sathekge MM. Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038 [Abstract] [Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Oct; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
3. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases. Lawal IO, Mokoala KMG, Mahapane J, Kleyhans J, Meckel M, Vorster M, Ebenhan T, Rösch F, Sathekge MM. Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485 [Abstract] [Full Text] [Related]
4. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer? Raju S, Sharma A, Patel C, Sahoo R, Das CJ, Kumar S, Sharma A, Kumar R. Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451 [Abstract] [Full Text] [Related]
5. Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis. Zhao G, Ji B. AJR Am J Roentgenol; 2022 Sep; 219(3):386-395. PubMed ID: 35441529 [Abstract] [Full Text] [Related]
6. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ. Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246 [Abstract] [Full Text] [Related]
7. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT. Caglar M, Tuncel M, Yildiz E, Karabulut E. Ann Nucl Med; 2020 Dec; 34(12):932-941. PubMed ID: 32975741 [Abstract] [Full Text] [Related]
8. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C. Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844 [Abstract] [Full Text] [Related]
9. Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT. Janssen JC, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G, Hamm B, Makowski MR. Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400 [Abstract] [Full Text] [Related]
10. Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET/CT in prostate cancer? Simsek DH, Sanli Y, Civan C, Engin MN, Isik EG, Ozkan ZG, Kuyumcu S. Ann Nucl Med; 2020 Jul; 34(7):476-485. PubMed ID: 32394269 [Abstract] [Full Text] [Related]
11. The diagnostic accuracy of 68Ga-PSMA PET/CT versus 99mTc-MDP bone scintigraphy for identifying bone metastases in persons with prostate cancer: A systematic review. Daniels H, Gilbert R, Bonin L. J Med Imaging Radiat Sci; 2023 Sep; 54(3):545-555. PubMed ID: 37211439 [Abstract] [Full Text] [Related]
12. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T. Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731 [Abstract] [Full Text] [Related]
17. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [Abstract] [Full Text] [Related]
18. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, Tamaki N, Schwaiger M, Maurer T, Eiber M. Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607 [Abstract] [Full Text] [Related]
19. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68 Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant? Chen MY, Franklin A, Yaxley J, Gianduzzo T, McBean R, Wong D, Tatkovic A, McEwan L, Walters J, Kua B. BJU Int; 2020 Sep; 126(3):396-401. PubMed ID: 32592330 [Abstract] [Full Text] [Related]
20. Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer. Fennessy N, Lee J, Shin J, Ho B, Ali SA, Paschkewitz R, Emmett L. J Med Imaging Radiat Oncol; 2017 Dec; 61(6):739-744. PubMed ID: 28623852 [Abstract] [Full Text] [Related] Page: [Next] [New Search]